Aktie A2QPM3 BIOTECH ACQUISITION COMPANY
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Biotech Acquisition Company

Aktien

A2QPM3

KYG1125A1085

BIOT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
BIOTECH ACQUISITION CO : Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
Biotech Acquisition to Dissolve, Liquidate
Biotech Acquisition Company(NasdaqCM:BIOT) dropped from NASDAQ Composite Index
Biotech Acquisition Company Announces Liquidation
Biotech Acquisition Company Announces Liquidation
BIOTECH ACQUISITION CO : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)
BIOTECH ACQUISITION CO : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
Biotech Acquisition Says New Sponsor to Make Additional Contributions Related to Proposed Business Combination Extension
Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment
BIOTECH ACQUISITION CO : Entry into a Material Definitive Agreement (form 8-K)
Biotech Acquisition Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
BIOTECH ACQUISITION CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
BIOTECH ACQUISITION CO : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
Biotech Acquisition Company announced that it expects to receive $0.25 million in funding
BIOTECH ACQUISITION CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference
BIOTECH ACQUISITION CO : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
Biotech Acquisition : and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement - Form 8-K
Biotech Acquisition, Blade Therapeutics Agree to Terminate Merger Agreement
BIOTECH ACQUISITION CO : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QPM3 Aktie
  4. Nachrichten Biotech Acquisition Company
  5. Andere Sprachen